Kidney failure

NYU Langone Health Awarded $13 Million to Create National Center to Promote Diabetes Equity Research

Retrieved on: 
Tuesday, February 6, 2024
Olive, Partnership, NYU Langone Health, Digestive, Family, Kidney failure, Public, Prediabetes, Nerve, Research, Health equity, MD, Caregiver, Patient, UCLA, Kidney, Paratriathlon, Olive View–UCLA Medical Center, School, Organization, American Diabetes Association, Social medicine, MPH, Diabetes, Education, AUC, Trust, Bangladesh Technical Education Board, Community, Type 2 diabetes, Workforce, African Americans, Pharmaceutical industry

To generate more community-engaged diabetes research, the National Institute of Diabetes and Digestive and Kidney Diseases, a division of the National Institutes of Health, has pledged $13 million to NYU Langone Health, Albert Einstein School of Medicine/Montefiore Health System, and UCLA School of Medicine to create the National Center for Engagement in Diabetes Equity Research (CEDER), the first of its kind.

Key Points: 
  • To generate more community-engaged diabetes research, the National Institute of Diabetes and Digestive and Kidney Diseases, a division of the National Institutes of Health, has pledged $13 million to NYU Langone Health, Albert Einstein School of Medicine/Montefiore Health System, and UCLA School of Medicine to create the National Center for Engagement in Diabetes Equity Research (CEDER), the first of its kind.
  • Co-led by Nadia Islam, PhD, associate professor in the Institute for Excellence in Health Equity at NYU Langone, CEDER will create a centralized national infrastructure designed to foster community engagement and participation of diverse populations in Type 2 diabetes research.
  • "It is our hope that everyone committed to advancing equity in diabetes research and care can access the support and mentorship they need."
  • CEDER is funded by the National Institute of Diabetes and Digestive and Kidney Diseases.

The uncertain fate of patients needing life-saving dialysis treatment in Gaza

Retrieved on: 
Tuesday, February 6, 2024
Kidney failure, Incubator, Nephrology, The Book of Healing, Al Jazeera, Family, Dialysis, Interview, Conditional sentence, United Nations Security Council, Al-Aqsa, Ambulance, Hospital, Courage, Nursing, The National (Abu Dhabi), UNRWA, Human Rights Watch, Patient, Respiratory failure, Food, Cardiac arrest, Freedom, MSF, Atrocity, Assault, World Health Organization, Speech, Kidney disease, Water supply, Physician, Water, United Nations, Bomb, Global health, UN, Gun, Insulin, Heart failure, Risk, Burn, Cancer, Internal medicine, WHO, Woman

The WHO says that, as of Jan. 5, there have been more than 600 attacks on health-care facilities, with 26 out of 36 hospitals in Gaza severely damaged and 79 ambulances targeted.

Key Points: 
  • The WHO says that, as of Jan. 5, there have been more than 600 attacks on health-care facilities, with 26 out of 36 hospitals in Gaza severely damaged and 79 ambulances targeted.
  • Over 300 health-care workers have been killed and over 200 have been detained by Israeli forces.
  • This leaves patients with chronic life-threatening diseases, such as cancer, heart failure and end-stage kidney disease, with severely limited access to the ongoing medical care they need to survive.

Patients unable to access care for chronic conditions

  • As nephrologists and internal medicine physicians, we are gravely concerned about patients in Gaza with chronic diseases who are unable to access care.
  • There are more than 1,100 dialysis patients, including 38 children, in Gaza.
  • Without adequate dialysis, fluid and toxins accumulate and patients typically die within days to weeks from respiratory failure or cardiac arrest.
  • But in a health-care system under assault, patients are fortunate to receive any dialysis at all.

Patients needing life-saving treatment

  • She then attempted to access dialysis at Al-Awda and Kamal Adwan hospitals, but both facilities had insufficient capacity to treat him.
  • This is a tremendous challenge for dialysis patients who are faced with the uncertainty of when, where or if they will access their life-saving therapy.
  • Anssam, age 12, was displaced from Jabaliya in northern Gaza to seek treatment in Deir El Balah in central Gaza.
  • She had gone 15 days without dialysis and had to leave with her mother to receive life-saving medical treatment.

Loss of medical personnel

  • Beyond the destruction of health-care facilities and a critical shortage of supplies, the loss of medical personnel may have the most devastating and longest-lasting impact on the health-care system in Gaza.
  • He had hopes to expand dialysis care in Gaza and build a nephrology educational training program.
  • His loss resonated far beyond his family, patients and colleagues in Gaza.
  • We join the UN, the WHO, MSF and the British Medical Association, along with millions around the world, who call for an immediate ceasefire and unimpeded humanitarian aid.


The authors do not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

Dog care below freezing − how to keep your pet warm and safe from cold weather, road salt and more this winter

Retrieved on: 
Tuesday, January 30, 2024
Weather, Death, Snow, Health, Frostbite, Kidney, Kidney failure, Temperature, Veterinarian, Seizure, Dehydration, Dog, University, Pet, Element, Freezing, Risk, Environment, Irritation, Skin, Lethargy, Antifreeze, Water, Cat, Socialization, Shivering, Hypothermia, Season, Pain, Ethylene glycol, Veterinary medicine

But in much of the country, when winter rolls around, previously hospitable conditions can quickly turn chilly and dangerous for people and pups alike.

Key Points: 
  • But in much of the country, when winter rolls around, previously hospitable conditions can quickly turn chilly and dangerous for people and pups alike.
  • Winter brings some unique challenges for dog owners, since dogs still need activity and socialization during colder seasons.
  • Studies have shown that dog owners are almost 50% less likely to walk their dogs when the weather gets cold.

Breed and age differences

  • A short-coated dog like a Chihuahua is much more susceptible to the dangers of cold weather than a thick-coated husky.
  • Age also affects cold-weather resilience.

When is my dog too cold?

  • A good rule to live by is if it is too cold for you, it is too cold for your dog.
  • Getting your dog a sweater or jacket and paw covers can provide them with protection from the elements and keep them comfortable.
  • Veterinarians also recommend closely monitoring your dog and limiting their time outside when the temperature nears the freezing point or drops below it.

Road salt dangers


Road salt that treats ice on streets and sidewalks can also harm dogs. When dogs walk on the salt, the sharp, rough edges of the salt crystals can irritate the sensitive skin on their paws.

  • Some companies make pet-safe salt, but in public it can be hard to tell what type of salt is on the ground.
  • You can also keep their paw fur trimmed to prevent snow from balling up or salt collecting in the fur.

Antifreeze risks

  • Some people pour antifreeze into their toilets when away from their home to prevent the water in the toilet from freezing.
  • Antifreeze is an exceptionally dangerous chemical to dogs and cats, as it tastes sweet but can be deadly when ingested.
  • If a pet ingests even a small amount of antifreeze, the substance causes a chemical cascade in their body that results in severe kidney damage.


Erik Christian Olstad does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

New York Women in Film & Television Announces Science in Motion Screening Series in Partnership with BAM

Retrieved on: 
Tuesday, January 30, 2024
Woman, National Science Foundation, Kidney failure, Collection, STEM, Diabetes, Partnership, Filmmaking, NSF, Q&A, Green New Deal, Singing, NASA, NEA, Brooklyn Academy, Marriage, Powder metallurgy

The six-week free series features STEM-focused narrative and documentary films with filmmaker Q&A's

Key Points: 
  • New York, New York--(Newsfile Corp. - January 29, 2024) - New York Women in Film & Television (NYWIFT) is proud to present the Science in Motion Screening Series in partnership with BAM (Brooklyn Academy of Music), a collection of groundbreaking contemporary films that delve into science and technology in the modern world.
  • The program is free and open to the public, presented in partnership with the National Science Foundation (NSF) with support from the National Endowment for the Arts (NEA).
  • "Since early childhood I have been fascinated by the intersection of STEM and the media, exploring how film can expose us to all of the innovations science has to offer.
  • "BAM is thrilled to partner with NYWIFT to spotlight these extraordinary and groundbreaking films.

JDRF Awards $9 Million US for Phase 3 Type 1 Diabetes Kidney Disease Clinical Trial, Joins The Kidney Foundation of Canada in Driving Research to Treat Kidney Disease

Retrieved on: 
Monday, January 22, 2024
Diabetes, Patient, Research, Diabetic nephropathy, Kidney, Kidney failure, Person, T1D, CIHR, SGLT2, Team, University, Kidney disease, Joslin Diabetes Center, Risk, KFOC, Type 2 diabetes, Safety, Public, University of Toronto, SGLT, JDRF, Clinical trial, University Health Network, Pharmaceutical industry

Kidney disease remains a life-threatening complication for those living with diabetes.

Key Points: 
  • Kidney disease remains a life-threatening complication for those living with diabetes.
  • Almost half of kidney failure cases are caused by diabetes, and an estimated one out of three people with T1D develop significant kidney disease.
  • SUGARNSALT is one of the largest T1D focused kidney disease studies in the world, and it is the only phase 3 clinical trial targeting major kidney disease outcomes.
  • "The Kidney Foundation of Canada is proud to be one of the founding partners on this significant investment to support innovative strategies to treat diabetic kidney disease.

Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations

Retrieved on: 
Thursday, January 25, 2024
Patient, Pharma, Therapy, IgA nephropathy, Kidney failure, SAN, Kidney disease, Medication, Immunoglobulin A, PMDA, Pharmaceutical industry

Renalys will hold regional rights to sparsentan for Japan, South Korea, Taiwan, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam.

Key Points: 
  • Renalys will hold regional rights to sparsentan for Japan, South Korea, Taiwan, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam.
  • “We’re pleased to partner with Renalys, a company led by distinguished renal experts with a strong track record of launching kidney disease treatments,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics.
  • As part of the collaboration, Travere has obtained a minority equity stake in Renalys and will be eligible to receive tiered royalties on net sales of sparsentan in Japan, South Korea, Taiwan, and the specified Southeast Asian nations.
  • “Travere is a long-known leader in rare kidney disease, and we are proud to collaborate with this team.”

American Kidney Fund Announces April 30 as the First Annual APOL1-Mediated Kidney Disease (AMKD) Awareness Day

Retrieved on: 
Thursday, January 25, 2024
Vertex Pharmaceuticals, Apolipoprotein L1, Dialysis, Central African, Focal segmental glomerulosclerosis, Kidney failure, Health, Foreign policy, Kidney, FSGS, APOL1, Gene, AKF, Risk, Kidney disease, Genetic testing, Mutation, Disease, Congress, L1, Education, American Kidney Fund, Pharmaceutical industry

ROCKVILLE, Md., Jan. 25, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) is proud to announce that April 30, 2024 will mark the nation’s first ever AMKD Awareness Day .

Key Points: 
  • ROCKVILLE, Md., Jan. 25, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) is proud to announce that April 30, 2024 will mark the nation’s first ever AMKD Awareness Day .
  • Building on AKF’s educational campaign for the condition, AMKD Awareness Day aims to spread awareness of APOL1-mediated kidney disease (AMKD) , a spectrum of kidney diseases associated with variants (mutations) in the apolipoprotein L1 (APOL1) gene and linked to an increased risk for rapidly progressing kidney disease in people of Western and Central African descent.
  • People with two mutations are at higher risk of developing genetic forms of kidney disease such as focal segmental glomerulosclerosis (FSGS).
  • Additionally, AKF will provide resources and ways to engage and raise awareness of the important connection between APOL1 gene variants and kidney disease in the months ahead.

MemorialCare Heart & Vascular Institute at Orange Coast Medical Center Earns 4 out of 5 Three-Star Ratings for Coronary Artery Bypass Surgery

Retrieved on: 
Monday, January 29, 2024
Mortality, Anesthesiology, Family, Participation, M.D, Patient, ACSD, Intubation, Hospital, Kidney failure, Health, Surgeon, Survival, Society, Stroke, CHSD, STS, CABG, Disease, Database, Benchmarking, Task force, Physician

FOUNTAIN VALLEY, Calif., Jan. 29, 2024 /PRNewswire/ -- MemorialCare Orange Coast Medical Center cardiac surgeons have earned distinguished three-star ratings from The Society of Thoracic Surgeons (STS) for its patient care and outcomes in isolated coronary artery bypass grafting (CABG) procedures.  The three-star ratings were awarded in the categories of medication compliance, absence of morbidity, absence of mortality, and overall composite score. The three-star accolades denote the highest category of quality and place Orange Coast Medical Center among the elite cardiothoracic surgery programs in the United States and Canada.

Key Points: 
  • The three-star ratings were awarded in the categories of medication compliance, absence of morbidity, absence of mortality, and overall composite score.
  • The three-star accolades denote the highest category of quality and place Orange Coast Medical Center among the elite cardiothoracic surgery programs in the United States and Canada.
  • The star rating is calculated using a combination of quality measures for specific procedures performed by an STS Adult Cardiac Surgery Database participant.
  • Some important measures include absence of morbidity and mortality, percentage of rapid extubation, and use of arterial conduits.

Incretin Mimetic Drugs Overtake Insulin in Total Prescriptions and Costs for Commercially Insured Patients

Retrieved on: 
Wednesday, January 10, 2024
General Health, Professional Services, Pharmaceutical, Data Management, Payments, Technology, Health Technology, Health Insurance, Data Analytics, Insurance, Health, Diabetes, Patient, Dulaglutide, C-peptide, Kidney failure, Doctor of Pharmacy, Stroke, Heart failure, Prescription, Business development, Risk, Insulin, Pharmacy, CPR, Product management, Benchmarking, Pharmaceutical industry

An analysis by Cedar Gate Technologies found that incretin mimetic prescription medications (also known as GLP-1 agonists) have overtaken insulin in total prescriptions and cost among commercially insured patients.

Key Points: 
  • An analysis by Cedar Gate Technologies found that incretin mimetic prescription medications (also known as GLP-1 agonists) have overtaken insulin in total prescriptions and cost among commercially insured patients.
  • The data unveils a significant 36.1% increase in GLP-1 agonist prescriptions and a 43.4% surge in costs for these medications.
  • In contrast, insulin prescriptions experienced a 1.4% decrease during the same period, transitioning from the top-prescribed diabetes drug class in the preceding year to the second position on the list.
  • They accounted for $544 million and $487 million, respectively, in total costs in a single year for pharmacy claims included in Cedar Gate’s analysis.

Human medicines European public assessment report (EPAR): Mycamine, micafungin, Date of authorisation: 25/04/2008, Revision: 18, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024
Fungal infection, Liver, Marketing, Chills, INN, Risk, Leukopenia, Hypotension, Fungus, Hypertension, Nausea, DNA, Inflammation, Liver disease, Anatomy, IIA, CHMP, Diarrhea, Fever, Infection, ATC, Hepatomegaly, European, Neutrophil, Neoplasm, HIV, Tachycardia, Anemia, Hypocalcemia, Hypokalemia, Patient, Medical Subject Headings, Caspofungin, European Commission, Echinocandin, Kidney failure, International, Bilirubin, Neutropenia, Blood, Language, Thrombocytopenia, Magnesium, Select, Medicine, Vomiting, Phlebitis, Amphotericin B, Allergy, Fluconazole, Headache, Rat, Haematopoiesis, Committee, Checklist, Alkaline phosphatase, Rash, Medical device

Human medicines European public assessment report (EPAR): Mycamine, micafungin, Date of authorisation: 25/04/2008, Revision: 18, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Mycamine, micafungin, Date of authorisation: 25/04/2008, Revision: 18, Status: Authorised